149 related articles for article (PubMed ID: 2910787)
1. Second-look procedures in ovarian cancer patients receiving six vs. nine courses of platinum, adriamycin, cytoxan (PAC) chemotherapy: the SCPMG experience 1982-1985.
Watring W; Semrad N; Alaverdian V; Latino F; Pretorius G
Gynecol Oncol; 1989 Feb; 32(2):245-7. PubMed ID: 2910787
[TBL] [Abstract][Full Text] [Related]
2. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
3. The role of second-look laparotomy in the management of patients with stage II, III and IV ovarian cancers following chemotherapy with cisplatin, adriamycin and cyclophosphamide.
Kirwan PH; Naftalin NJ; Khanna S; Aukett RJ
Br J Obstet Gynaecol; 1986 Jun; 93(6):629-33. PubMed ID: 3730331
[TBL] [Abstract][Full Text] [Related]
4. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
Hunter RE; Griffin TW; Stevens S; Roman LD; Bokhari F; Reale FR; Tak WK; Fitzgerald TJ; Dillon MB; Rose PG
Cancer; 1991 Nov; 68(9):1890-4. PubMed ID: 1655227
[TBL] [Abstract][Full Text] [Related]
5. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer].
Kobayashi H; Hayata T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1936-42. PubMed ID: 2592816
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy.
Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ
Oncology; 1990; 47(2):109-11. PubMed ID: 2314822
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
9. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
[TBL] [Abstract][Full Text] [Related]
10. Second-look laparotomy in ovarian carcinoma patients after 8 and after 12 courses of cisplatin-based chemotherapy.
Menczer J; Ben-Baruch G; Modan M; Brenner H
Gynecol Obstet Invest; 1989; 27(2):102-4. PubMed ID: 2731767
[TBL] [Abstract][Full Text] [Related]
11. Intermittent intensive combination chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (cyclic PAC chemotherapy) for ovarian cancer.
Inoue M; Nakanishi K; Ueda G; Tanizawa O
Am J Clin Oncol; 1992 Feb; 15(1):1-6. PubMed ID: 1550076
[TBL] [Abstract][Full Text] [Related]
12. [Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers].
Inoue M; Nakanishi K; Nakazawa A; Ogawa H; Shimizu H; Saitoh J; Tanaka Y; Ueda G; Tanizawa O
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):347-52. PubMed ID: 2358719
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO).
Gadducci A; Brunetti I; Bruzzone M; Carnino F; Chiara S; Conte PF; Fioretti P; Foglia G; Ragni N
Eur J Gynaecol Oncol; 1992; 13(1 Suppl):36-9. PubMed ID: 1511712
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic results in advanced ovarian cancer].
Kleinmanns G; Dauer W; Knief JJ; Westerhausen M
Onkologie; 1983 Aug; 6(4):206-9. PubMed ID: 6415561
[TBL] [Abstract][Full Text] [Related]
15. Tumor debulking followed by immediate combination chemotherapy in advanced ovarian carcinoma. Phase II.
Vardi JR; Tadros GH; Zamurovic D; Rafla SD
Acta Obstet Gynecol Scand; 1992 Jul; 71(5):361-7. PubMed ID: 1326212
[TBL] [Abstract][Full Text] [Related]
16. The feasibility of early administration of combination chemotherapy following cytoreductive surgery and second-look operation in patients with stage III ovarian carcinoma: a pilot study.
Vardi JR; Rafla SD; Malhotra C; Tadros G; Charney T; Shebes M; Berkowitz BJ; Kehoe JE; Tancer LM
Gynecol Oncol; 1989 Jul; 34(1):12-5. PubMed ID: 2737518
[TBL] [Abstract][Full Text] [Related]
17. The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer.
Bertelsen K; Hansen MK; Pedersen PH; Larsen G; Nyland M; Jacobsen M; Andersen JE
Br J Obstet Gynaecol; 1988 Dec; 95(12):1231-6. PubMed ID: 3224088
[TBL] [Abstract][Full Text] [Related]
18. Place of second-look laparotomy after 18 courses of chemotherapy in epithelial ovarian cancer.
Ngan HY; Wong LC; Ma HK
Aust N Z J Obstet Gynaecol; 1989 Feb; 29(1):52-4. PubMed ID: 2562603
[TBL] [Abstract][Full Text] [Related]
19. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status.
Berek JS; Hacker NF; Lagasse LD; Poth T; Resnick B; Nieberg RK
Obstet Gynecol; 1984 Aug; 64(2):207-12. PubMed ID: 6539884
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study.
Randall ME; Barrett RJ; Spirtos NM; Chalas E; Homesley HD; Lentz SL; Hanna M
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):139-47. PubMed ID: 12118543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]